Free Trial

Doximity (NYSE:DOCS) Stock: Insider Siddharth Sitaram Sells 2,613 Shares

Doximity logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Doximity CAO Siddharth Sitaram sold 2,613 shares at an average price of $30.68, generating $80,166.84. The Rule 10b5-1 sale was intended to cover tax withholding on vested equity awards, leaving him with 101,432 shares.
  • Doximity shares traded near $30.81, with a $5.49 billion market capitalization. The company recently beat quarterly EPS estimates, reporting $0.29 versus the $0.16 consensus, while revenue rose 7.3% year over year to $156.62 million.
  • Analyst sentiment is mixed, with the stock carrying an overall “Hold” rating and an average price target of $30.73. Doximity also faces a securities-fraud class-action overhang, alongside continued institutional ownership of 87.19%.
  • MarketBeat previews the top five stocks to own by November 1st.

Doximity, Inc. (NYSE:DOCS - Get Free Report) CAO Siddharth Sitaram sold 2,613 shares of Doximity stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $30.68, for a total transaction of $80,166.84. Following the completion of the sale, the chief accounting officer owned 101,432 shares in the company, valued at approximately $3,111,933.76. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Siddharth Sitaram also recently made the following trade(s):

  • On Tuesday, September 15th, Siddharth Sitaram sold 2,077 shares of Doximity stock. The shares were sold at an average price of $26.02, for a total transaction of $54,043.54.
  • On Thursday, August 13th, Siddharth Sitaram sold 1,770 shares of Doximity stock. The shares were sold at an average price of $24.94, for a total value of $44,143.80.

Doximity Stock Performance

Shares of NYSE DOCS traded down $0.69 during mid-day trading on Friday, hitting $30.81. 3,582,714 shares of the stock traded hands, compared to its average volume of 3,989,128. The company has a market cap of $5.49 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 23.40 and a beta of 1.22. The stock has a fifty day moving average price of $26.68 and a 200-day moving average price of $23.58. Doximity, Inc. has a 52 week low of $17.15 and a 52 week high of $71.37.

Doximity (NYSE:DOCS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.16 by $0.13. The firm had revenue of $156.62 million for the quarter. Doximity had a net margin of 25.48% and a return on equity of 18.06%. The business's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.36 EPS. As a group, sell-side analysts predict that Doximity, Inc. will post 0.74 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Freedom Capital lowered Doximity from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 8th. Bank of America reaffirmed an "underperform" rating and issued a $20.00 target price (down from $38.00) on shares of Doximity in a report on Monday, June 29th. Truist Financial upped their target price on shares of Doximity from $19.00 to $24.00 and gave the stock a "hold" rating in a research note on Thursday, August 13th. Piper Sandler reiterated an "overweight" rating and issued a $47.00 target price (up from $42.00) on shares of Doximity in a research note on Friday, August 7th. Finally, Citigroup cut shares of Doximity to an "underperform" rating in a report on Monday, June 29th. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $30.73.

Check Out Our Latest Research Report on Doximity

Trending Headlines about Doximity

Here are the key news stories impacting Doximity this week:

  • Positive Sentiment: Doximity extended its 13-year alliance with U.S. News, supporting physician searches, appointment booking and hospital rankings. The partnership could reinforce user engagement and patient-access offerings. Doximity Deepens U.S. News Alliance to Improve Patient Access to Care
  • Neutral Sentiment: Doximity will release fiscal 2027 second-quarter results on November 5, giving investors the next major opportunity to assess growth, advertising trends and management’s outlook. Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026
  • Negative Sentiment: Several law firms publicized a securities-fraud class action against Doximity and certain individuals, including co-founder and former Chief Strategy Officer Nate Gross. The allegations reportedly concern statements that Doximity could gain market share while older advertising formats were losing ground to programmatic and social-media competitors; the claims have not been established in court.
  • Negative Sentiment: Investors who purchased DOCS shares between August 8, 2024 and May 13, 2026 are being reminded that November 16, 2026 is the deadline to seek appointment as lead plaintiff. Repeated announcements from Robbins Geller, SBS Law, Kaplan Fox, Rosen, Pomerantz, Bronstein Gewirtz Grossman and other firms increase the visibility of the legal overhang and could weigh on sentiment. DOCS Investor Alert

Institutional Trading of Doximity

A number of institutional investors have recently made changes to their positions in DOCS. Versant Capital Management Inc raised its holdings in shares of Doximity by 1,176.9% during the third quarter. Versant Capital Management Inc now owns 1,826 shares of the company's stock valued at $52,000 after purchasing an additional 1,683 shares during the last quarter. Parallel Advisors LLC boosted its holdings in Doximity by 111.0% in the first quarter. Parallel Advisors LLC now owns 2,560 shares of the company's stock worth $60,000 after purchasing an additional 1,347 shares during the last quarter. Fortitude Family Office LLC boosted its holdings in Doximity by 31,271.4% in the third quarter. Fortitude Family Office LLC now owns 2,196 shares of the company's stock worth $62,000 after purchasing an additional 2,189 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Doximity by 937.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,833 shares of the company's stock worth $66,000 after purchasing an additional 2,560 shares during the period. Finally, Continuum Advisory LLC bought a new stake in Doximity in the 2nd quarter worth approximately $67,000. Hedge funds and other institutional investors own 87.19% of the company's stock.

Doximity Company Profile

(Get Free Report)

Doximity, Inc operates a digital platform designed for U.S. medical professionals. Its network enables physicians, nurse practitioners, physician assistants and other healthcare providers to connect with colleagues, exchange clinical information and access professional resources.

The company offers tools for telehealth and care coordination, including video and phone-based communication services, as well as digital faxing and secure messaging capabilities. Doximity also provides medical news and research content tailored to healthcare professionals.

Doximity generates additional business through recruiting and marketing solutions that help healthcare organizations reach clinicians and promote employment opportunities, services and products.

Featured Stories

Insider Buying and Selling by Quarter for Doximity (NYSE:DOCS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Doximity Right Now?

Before you consider Doximity, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.

While Doximity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines